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 The clinical importance for the early detection of insulin resistance 
 
In the early 1970’s, a population-based study of approximately 5000 subjects was 
conducted to assess the clustering and frequency of five atherosclerotic risk factors 
including cholesterol, triglycerides, systolic blood pressure, obesity, and cigarette 
smoking (Criqui, Barret-Conner, Holdbrook, Austin, & John, 1980).  In a percentile 
analysis of this study published in 1980, Criqui et al. found subjects at or above the 70
th 
or 90
th percentiles for one risk defined in the study were more likely to be at or above 
similar percentiles for the other risk factors.  This clustering was most evident among the 
subjects in the highest percentiles of the population.  Later, in a follow up study 
published in 1983, the same clustering of atherosclerotic risks was found to be more 
prevalent in diabetic participants (Wingard, Barrett-Conner, Criqui, & Suarez, 1983).  By 
1988, Gerald Reaven, an endocrinologist at Stanford School of Medicine had begun 
recognizing insulin resistance and hyperinsulinemia as a potential pathophysiology 
linking the clustering of the previously described risk factors.  Reaven made many of his 
observations through combinations of human and laboratory rat studies; describing a 
cluster of risks he deemed Syndrome X.  He found these risks to be present not only in the 
diabetic population, but in individuals with impaired glucose tolerance; concluding that 
the underlying insulin resistance and subsequent hyperinsulinemia were responsible for 
atherogenic changes (Reaven, 1988).  Today, the term Metabolic Syndrome is used to 
describe the presence of dyslipidemia, hypertension, and hyperglycemia; commonly 
associated with obesity.  This clustering of cardiovascular risks factors is associated with 
an increased risk of coronary artery disease and diabetes (Lempiainen, Mykkanen, 
Pyorala, Laasko, & Kussisto, 1999).   2
Current understanding of the syndrome is limited to individual precipitating 
factors, hypertension, abdominal obesity, hypertriglyceridemia, hyperglycemia, and low 
high-density lipoprotein levels. These precipitating factors negatively impact endothelial 
function, serum lipids, and increase the risk of CHD, stroke, and diabetes (National 
Cholesterol Education Program, 2001).  A definitive etiology of the cluster has yet to be 
identified, although insulin resistance has long been suspected.  The National Cholesterol 
Education Program (NCEP) Adult Treatment Panel III (ATP III) established guidelines in 
2001 for metabolic syndrome.  The diagnosis of metabolic syndrome is made when 3 or 
more of risk determinants in Table 1 are present.  In their findings, the ATP III 
recommend metabolic syndrome as a secondary goal of therapy for atherosclerotic risk 
reduction behind the primary goal of low density-lipoprotein cholesterol reduction; citing 
the associated increased risk for (CHD) coronary heart disease (Ford, Giles, & Dietz, 
2002). 
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Prevalence 
  Little information on the prevalence of the metabolic syndrome was available until 
the establishment of a unifying definition and criteria established in 2001 by the NCEP-
ATPIII.  Ford et al. (2002) were able to estimate the age-adjusted prevalence of metabolic 
syndrome to be 23.7% in the United States by the criteria specified by the ATP III and 
findings of the Third National Health and Nutrition Examination Survey (NHANES III); 
collected from a sample population of US non-institutionalized civilians between 1988 
and 1994.  
Ford further noted a positive correlation of increasing prevalence of metabolic 
syndrome with increasing age; those aged 20-29 years versus those ages 60-69 years 
demonstrated a prevalence of 6.7% and 43.5%, respectively (Ford et al ., 2002).  Among 
the participants, Mexican Americans displayed the highest age-adjusted prevalence of 
metabolic syndrome (31.9%) followed by whites and African Americans, 23.8% and 
21.6%, respectively.  The age-adjusted prevalence for men and women of all ethnicities 
showed little disparity, 24.0% and 23.4% respectively.  Applying these findings to the 
2000 census information, approximately 47million (22%) of the US populations would 
meet diagnostic criteria for metabolic syndrome (Ford et al.).  Ford cautions current 
prevalence rates may actually be higher citing increasing trends of obesity in the US since 
the NHANES III was conducted.  The Behavioral Risk Factor Surveillance Survey 
(BRFSS) conducted in 2000 found a 61% increase in obesity since 1991 (Cook, 
Weitzman, Auinger, Nguyen, & Dietz, 2003).   
In 2003, Cook et al. determined that the metabolic syndrome was present in 4.2% 
of the subjects aged 12-19 years-old in the NHANES III study.   In the overweight 
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children of this age range, defined as a BMI equal to or greater than the 95
th percentile for 
age and gender, 28.7% met diagnostic criteria in comparison to 0.1% of those with a BMI 
below the 85
th percentile for their age and gender.  Based on these population-weighted 
estimates, nearly 910,000 adolescents, approximately 4% of all adolescents in the United 
States, met the criteria for metabolic syndrome
 (Cook et al.).  Current NHANES data 
suggests 15% of adolescents surveyed in 1999-2000 are overweight (BMI ≥95%); when 
applied to the 2000 Census data and the prevalence rate established by Cook et al., 
approximately 1.4 million adolescents aged 12-19 have metabolic syndrome.  
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Metabolic Syndrome and Insulin Resistance 
The association of impaired fasting glucose/impaired glucose tolerance (IFG/IGT) 
and the metabolic syndrome has long been recognized.   Recently, studies have begun to 
show the association between insulin resistance, metabolic syndrome, and diabetes 
(Meigs et al., 2003).  In the Bruneck Study (Bonora et al., 1998), the purpose was to 
assess the prevalence of insulin resistance in populations of patients displaying IGT, non-
insulin dependant diabetes mellitus (NIDDM), hyperuricemia, hypertension, and 
dyslipidemia.  Insulin resistance in this study was defined using the Homeostasis Model 
Assessment for Insulin Resistance (HOMAIR), calculated by taking the product of fasting 
serum insulin (U/ml) x fasting plasma glucose (mmol/l), divided by the constant 22.5 
(Matthews et al., 1985).  Low HOMAIR values are indicative of high insulin sensitivity, 
whereas lower values suggest insulin resistance; defined in the Bruneck Study as equal to 
or greater than the lower limit of the upper quintile of HOMAIR distribution values in 
normal subjects (BMI ≤25 kg/m
2 with no metabolic abnormalities).  This study 
demonstrated the prevalence of insulin resistance in IGT and NIDDM subjects was 
65.9% and 83.9% respectively. Eighty eight percent of the subjects with low high-density 
lipoprotein (HDL) levels displayed insulin resistance, as did 84.2% of those with 
hypertriglyceridemia.  The prevalence of insulin resistance in subjects with the 
combination of all features including IGT, non-insulin dependant diabetes mellitus 
(NIDDM), hyperuricemia, hypertension, and dyslipidemia was 95.2% (Bonora et al., 
1998).   In a similar study using the World Health Organization (WHO) criteria (Table 2) 
for metabolic syndrome, similar prevalence rates of IFG/IGT were found (Isomaa et al., 
2001).   Metabolic syndrome, as defined by the WHO, omits the use of fasting glucose 
   6
defined by NCEP as criteria. However, they add the use of a urinary albumin excretion 
rate as an additional guideline; 2 of the 4 criteria used in the WHO definition are required 
for diagnosis (Alberti & Zimmer, 1998). 
In a 7-year follow up of the San Antonio Heart Study, prediabetic subjects who 
had converted to NIDDM were compared among each other based on insulin sensitivity 
and insulin secretion.  Insulin resistance was defined as levels at or above the median for 
HOMAIR in the non-diabetic population of this study.  Insulin secretion was measured 
using an early insulin secretion response to an oral glucose load; calculated by change in 
insulin/change in glucose through the first 30 min (∆I30-0/∆G30-0).  Again, secretory 
defects were defined by levels at or below the median ∆I30-0/∆G30-0 for the non-diabetic 
population in this study.  As a whole, those that had developed NIDDM displayed 
elevated levels of blood pressure, triglycerides, and low HDL cholesterol over those in 
the study who did not convert to NIDDM.  However, within the converters, subjects 
found to have decreased insulin sensitivity (insulin resistance) had a stronger risk of 
atherosclerosis and significantly higher elevated blood pressure, triglycerides, and low 
HDL cholesterol over their NIDDM counterparts with only an insulin secretory defect 
(Haffner, Mykkanen, Festa, Burke, & Stern, 2000). 
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Insulin Action and Endothelial Dysfunction  
Impaired insulin action occurs when the body tissues no longer respond to a 
normal concentration of insulin.  The mechanism in which insulin resistance develops is 
not fully understood, however, increasing evidence indicates it may rely on a multitude of 
factors including diet (Purnell et al., 2000), inactivity (Pate et al., 1995), genetics (Taylor 
et al., 1992), and visceral obesity (St-Pierre et al., 2002).  Glucose removal by muscle or 
adipose tissue and the regulation of hepatic glucose production are commonly interrupted 
pathways of insulin resistance (Reaven, 1988).  When plasma glucose levels become 
elevated, the β-cells in pancreas respond by secreting more insulin to maintain a 
euglycemic state (James, 1992).  With time, the β-cells will no longer maintain these 
elevated levels of secretion, resulting in impaired glucose tolerance (IGT) and 
hyperglycemia.  Chronically elevated levels of insulin, as in insulin resistance, often 
result in metabolic abnormalities such as decreased HDL cholesterol, increased 
triglycerides (TG) levels, and increased levels of smaller, dense LDL cholesterol in 
addition to endothelial dysfunction.   
Inside endothelial target cells, insulin activates multiple pathways including 
phosphatidylinositol 3-kinase pathway (PI3K) which works in glucose uptake and 
metabolism in a manner similar to glucose metabolism in the liver, muscle, and fat cells.  
Additionally, the PI3K pathway has also been shown to regulate insulin-dependant 
endothelial nitric oxide (NO) production; in this manner insulin acts a vasodilator (Zeng 
et al., 2000).  The presence of vasodilators promotes vascular dilation and provides an 
antiatherogenic action (Vallance, Collier, & Moncada, 1989).  Nitric oxide is known to 
produce smooth muscle relaxation, vasodilation, and inhibition of VSMC growth, 
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migration, in addition to prevention of monocyte adhesion (Celermajer, 1997); many of 
which contribute to atherosclerosis and hypertension.  Nitric oxide-mediated endothelial 
dysfunction
 has been found in NIDDM as well as obese subjects (Steinberg et al., 1997).  
The disruption of the PI3K pathway is the potential link of insulin resistance to 
hypertension, atherosclerosis, hyperglycemia, and associated metabolic abnormalities 
seen with the metabolic syndrome (Shephard, Withers, & Siddle, 1998).   
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Cardiovascular Risk Factors  
Traditional risk factors for atherosclerosis and endothelial dysfunction have long 
been studied; including hypertension, increasing age, smoking, and hypercholesterolemia 
(Celermajer & Sorensen, 1992).   In 1998, Haffner et al. showed the associated risk of 
CHD for subjects with NIDDM to be equivalent to non-diabetic subjects with a prior 
cardiovascular event (Haffner et al., 1998).  More current studies have begun to focused 
on an alternate subset of risk factors for endothelial dysfunction and CHD, assessing their 
potential predication of cardiovascular events; this includes hypertriglyceridemia 
(Lundman, Eriksson, Schenck-Gustafsson, Karpe, & Tornvall, 1997) and elevated levels 
of free fatty acids (Steinberg et al., 1997).  Insulin resistance, as well, has been 
significantly linked to CHD (Lempiainen et al., 1999) and endothelial dysfunction 
(Steinberg et al., 1996).  Recent evidence supports insulin resistance as an independent 
predictor of cardiovascular events (Pyorala, Miettinen, Halonen, Laasko, & Pyorala, 
2000). 
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Insulin Resistance and Dyslipidemia 
The atherogenic lipid and lipoprotein abnormalities of the metabolic syndrome 
and associated insulin resistance consists of decreased HDL cholesterol, increased 
triglycerides (TG) levels, increased levels of smaller, dense LDL cholesterol and elevated 
levels of apolipoprotein-B.  The association of insulin resistance and dyslipidemia in 
metabolic syndrome has multiple proposed mechanisms.  One suggested pathway relates 
to dyslipidemia based on the presence of insulin resistant adipocytes; decreased insulin 
sensitivity in these adipose cells is thought to be the initial step of dyslipidemia.  
Adipocytes are specifically enabled to store abundant amounts of free fatty acids (FFA) 
in the form of TG (Unger, 2002).  Fat cells will remove free fatty acids from plasma 
concentrations and combined them with glycerol, derived from glucose, to form TG.  
Additionally, molecules such as TG-rich very low-density lipoprotein cholesterol 
(VLDL) act as FFA vectors which are taken up, metabolized, and stored within the 
adipocytes.  The decreased action of insulin results in an increase in lipolytic active 
within the adipocytes, resulting in hydrolysis and the subsequent release of triglycerides 
raising serum FFA concentrations (Ginsberg, 2000).
  These acute elevations of FFA have 
been shown to show decreased glucose uptake in peripheral skeletal muscle (Kelley et al., 
2001) and result in further production of TG and VLDL in association with 
apolipoprotein B from the liver (McFarlane, Banerji, & Sowers, 2001).
VLDL cholesterol elevations precipitate further dyslipidemia and atherosclerotic 
risks.  Triglyceride-rich LDL particles are more readily hydrolyzed by lipoprotein lipase 
or hepatic lipase, resulting in a smaller, denser, more atherogenic (LDL) particle that has 
shown to provide independent risk value for CAD (Lamarche et al., 1997).  The manner 
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in which HDL cholesterol is regulated is not fully understood, however, low HDL-C is 
commonly associated with elevated triglycerides levels and insulin resistance (Zambon, 
Brown, Deeb, & Brunzell, 2001).  
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Assessment of Insulin Resistance 
The glucose clamp technique developed in 1979 by DeFronzo et al. has been 
considered the gold-standard for assessment of β-cell response to glucose (hyperglycemic 
clamp method) and insulin sensitivity (euglycemic clamp method).  The euglycemic 
clamp technique requires a constant insulin infusion with a variable glucose infusion 
adjusted to maintain a constant level of euglycemia; the rate of glucose infusion equates 
to the body’s tissue-uptake of glucose.  This rate of glucose removal provides a 
quantitative assessment of insulin action in the body (DeFronzo, Tobin, & Andres, 1979). 
Although the glucose clamp technique provides the best evaluation of insulin 
resistance, its application in larger study populations and clinical settings are limited due 
to its time consuming nature, inherent high cost, and increased level of sophistication.  
Bergman et al. (1979) developed a slightly more practical assessment of insulin 
resistance; the technique design involved a frequently sampled intravenous glucose 
tolerance test (FSIGTT) where a single glucose injection is followed by a single dose of 
insulin.  Plasma glucose concentrations are then repeatedly measured (22 samples) over 3 
hours post insulin injection (Bergman, Ider, Bowden, & Cobelli, 1979).  Additionally, 
Bergman later developed the minimal model technique to compliment this method.  
Minimal model was designed to calculate an insulin sensitivity index based on the 
dynamic relationship between glucose and insulin during a frequently sampled glucose 
tolerance test (Bergman, 1989).  Comparisons of the glucose clamp technique and FSIGT 
with minimal model assessment showed the two are similar in their ability to identify 
insulin resistance in NGT and IGT subjects, however, findings of the study demonstrate 
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FSIGTT lacks the same sensitivity as the glucose clamp in assessing insulin resistance 
among NIDDM subjects (Saad et al., 1994).  
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Simple Tests of Insulin Sensitivity 
Recent attempts have been aimed to develop an accurate index to assess insulin 
resistance using a single fasting blood sample.  Some of these techniques include the 
HOMAIR, oral glucose tolerance tests, fasting insulin, insulin-to-glucose ratio, and 
combinations of assorted values.   
• Homeostasis Model Assessment (HOMAIR) 
Mentioned earlier, the homeostasis model assessment (1985) uses a computer-
solved model of insulin and glucose interactions to plot various fasting plasma insulin 
and glucose combinations; levels that would be expected in various degrees of β-cell 
dysfunction and/or insulin resistance.  This array provides a graph to which measured 
fasting plasma insulin and glucose levels can be applied, allowing estimations of glucose 
sensitivity and β-cell function from a single fasting sample.  A simple formula for insulin 
resistance was derived from this model; calculated by taking the product of the [fasting 
serum insulin] (µU/ml) and [fasting plasma glucose] (mmol/l), divided by 22.5 
(Matthews et al. 1985).  
• Insulin-to-glucose ratio 
Developed by Caro in 1991, the insulin-to-glucose ratio is a formula similar to the 
HOMAIR equation for insulin resistance; the constant 22.5 in the denominator is omitted.  
In this model, insulin resistance is defined by any value lower than 6, calculated using the 
equation fasting plasma glucose (mg/dL) / fasting serum insulin (µU/ml).  This ratio is 
not without its limitations, because it depends on normal function of β-cells, it is not valid 
in anyone with a secretory defect, such as NIDDM (Caro, 1991). 
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• Insulin levels 
Laakso in 1993 utilized a more simple approach, investigating fasting insulin and 
insulin samples following an oral glucose tolerance test.  Compared with the euglycemic 
clamp technique, he found that insulin had different correlation values in assessment of 
insulin resistance between NGT (normal glucose tolerance), IGT, and NIDDM subjects.  
He eventually determined that for any insulin value, fasting insulin was the most useful in 
predicting insulin resistance (Laakso, 1993).  
• Insulin and Triglycerides  
Based on the assessment Laakso in NGT subjects, McAuley et al. (2001) took a 
different approach to assessing insulin resistance by evaluating fasting insulin levels in 
combination with various characteristics in normoglycemic patients including blood 
pressure, waist circumference, lipid profiles, BMI, liver enzymes, and glucose.  In the 
study population of NGT subjects, fasting insulin, fasting triglycerides, aspartate-
aminotransferase, waist circumference, and BMI were found to correlate best with insulin 
sensitivity among the tested variables (McAuley et al., 2001).   
  Many comparisons have been drawn between Bergman’s minimal model, the 
glucose clamp, insulin indices, and the homeostasis model assessment.  One such study 
(1995) of the insulin sensitivity models was based on association to (correlation), and 
consistency (coefficient of variable) with the glucose clamp.  Compared with HOMAIR 
and the other indices, minimal model was superior in both association and consistency in 
this study.  Although, HOMAIR and the insulin-to-glucose ratio correlated well in 
comparison, their respective coefficient of variation was significantly higher than that of 
the minimal model.  Matthews et al. noted this inconsistency within HOMAIR when first 
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developed the model in 1985 (Matthews et al.).  Despite inferior consistency compared 
with the minimal model, HOMAIR and the similarly derived IG ratio were marginally 
superior to the remaining insulin indices (Anderson et al., 1995).  The single fasting 
insulin value proved to have a moderate association with the glucose clamp and poor 
consistency when tried in a population consisting of NGT, IGT, and NIDDM subjects.  
Findings suggested single fasting insulin levels would yield varying values depending on 
the glucose tolerance of the subject; providing a higher coefficient of variation and 
limiting the models use without prior knowledge of glucose tolerance status in the subject 
(Anderson  et al.).   
  These findings were confirmed in a similar study in 1998 by Howard et al, 
suggesting that although some of these methods may provide alternatives for use in 
studies and trials, they do not provide a reasonable alternative for clinical assessment of 
insulin resistance in the general population (Howard et al., 1998).  The findings 
associated with combining fasting insulin and fasting triglycerides were not yet published 
and not assessed in these studies.   
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Clinical assessment of insulin resistance 
  Results of earlier studies found that the HOMAIR correlated well with the standard 
glucose clamp but was highly variable in its results, making the model unsuitable for 
clinical application.  In 1999, Emoto et al. used a log-transformed version of the 
HOMAIR equation (Log-HOMAIR) in their study, resulting in increased correlation with 
the euglycemic clamp over the standard HOMAIR model (Emoto et al., 1999).  Later that 
year, the log-transformed HOMAIR was assessed against the minimal model applied with 
a FSIGT, again, displaying a higher correlation than the original HOMAIR (Fukushima et 
al., 1999).   
   Recognizing this utility of a log-transformed equation, Katz et al. (2000) 
developed a related model to similar to Log HOMAIR, a quantitative insulin sensitivity 
check index (QUICKI) (Katz et al., 2000).  In his study, QUICKI (1/ [log (I0)] + [log 
(G0)]) was tried against the glucose clamp, a FSIGTT with minimal model analysis, and 
the older version of HOMAIR across NGT, IGT, and NIDDM subjects.  The results 
showed that QUICKI correlated better with the glucose clamp (r = 0.78) compared to the 
minimal model (r = 0.57) and the HOMAIR (r = 0.6) values found in this study (Katz et 
al.).  Later, it was recognized that measuring FFA as a component of the equation would 
improve the reliability of QUICKI as a screening tool.  In this population of non-obese, 
normoglycemic subjects, results nearly doubled in the correlation of the index with 
euglycemic clamp (r = 0.51 from r = 0.27) (Perseghin, Caumo, Caloni, Testolin, & Livio, 
2001).  This study also demonstrated that inclusion of FFA component improved the 
sensitivity of QUICKI to lower levels of insulin resistance in normoglycemic subjects.   
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These benefits were later confirmed and expanded to include the IGT populations as well 
(Rabasa-Lhoret et al., 2003).     
  In a comparison of log-transformed HOMAIR and the original formula for QUICKI 
to the glucose clamp, both models performed similarly (Mather et al., 2001).  The 
findings of the study suggest that both indices correlate highly to the glucose clamp in 
obese and NIDDM subjects, but comparatively weak among the lean subjects (r = 0.35-
0.4).  This study suggests that although improvements are still needed, these current 
approaches would be appropriate surrogate measures of insulin sensitivity.  Additionally, 
when compared to models based on fasting insulin alone, indices with inclusion of 
glucose measures such as Log-HOMAIR and QUICKI provide a more generalized and 
superior method for assessment of insulin resistance (Mather et al.). 
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Conclusions 
  The metabolic syndrome, although poorly defined until recently, has been 
recognized and studied since the early 1970’s.  Recognition and identification of these 
clustering risk factors has demarcated a population with greater risk for development of 
CAD and diabetes.  The underlying pathophysiology of the metabolic syndrome is not 
well under understood at this time.  Insulin resistance has long been considered to play an 
integral role; research conducted in the past decade has provided plausible mechanisms 
for IR which may explain associated physiologic changes.   
  The clinical importance and need for routine insulin resistance screening is clearly 
apparent by the increasing morbidity and mortality for those who develop CAD and 
diabetes, as well as the growing population of those meeting metabolic syndrome criteria.  
Unfortunately, recent attempts to identify IR through the use of computer models, 
calculations, and measured ratios have proven unsuccessful in large, general populations.  
Until a simple, cost-effective measure of insulin sensitivity is developed the best 
screening for IR is the clinical application of NCEP criteria.  
  Once identified as insulin resistant by NCEP guidelines, treatment should be 
aggressive for these patients; current ATP III guidelines suggest LDL-C treatment to goal 
as primary therapy.  The identification of the metabolic syndrome and IR, defined by 3 of 
5 NCEP criteria should be considered a more progressive disease state.  Treating LDL-C 
in these patients equivocates to symptomatic therapy, leaving the underlying resistance to 
insulin unchanged.  For this reason, the potential use of insulin sensitizers, such as 
thiazolidinediones, may prove to be more beneficial in treating the underlying 
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pathophysiology and should be further investigated for their use in the metabolic 
syndrome population.   
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Table 1 Diagnostic Criteria for Metabolic Syndrome, Guidelines of National 
Cholesterol Education Program: Adult Treatment Panel III (Ford et al ., 2002)   
 
Diagnosis of metabolic syndrome requires any 3 of the following: 
Abdominal obesity  Waist circumference 
•  Men  >102 cm (>40 in) 
•  Women  >88 cm (>35 in) 
Triglycerides   ≥150 mg/dl 
HDL cholesterol   
•  Men  <40 mg/dl 
•  Women  <50  mg/dl 
Blood pressure   ≥130/≥85 mmHg  
Fasting glucose  ≥110 mg/dl and <126 mg/dL 
 
 
 
Table 2 Diagnostic Criteria for Metabolic Syndrome, Guidelines of World Health 
Organization
 [23]
 
Diagnosis of metabolic syndrome requires any 2 of the following: 
Abdominal obesity  Waist circumference 
•  BMI  ≥30 kg/m
2  
•  Waist: Hip Ratio  >0.90 in men, >0.85 in women 
Dyslipidemia defined as one/both of:   
•  Triglycerides   ≥1.7 mmol/l 
•  HDL cholesterol   <0.9 mmol/l in men, <1.0 mmol/l in 
women 
Blood pressure   ≥160/≥90 mmHg or antihypertensive Tx 
Microalbuminuria Urinary  Albumin Excretion Rate  
(AER) ≥20 µg/min 
 
To convert mmol/l of HDL cholesterol to mg/dl, multiply by 38.67. 
To convert mg/dl of HDL cholesterol to mmol/l, divide by 38.67. 
 
To convert mmol/l of triglycerides to mg/dl, multiply by 88.57. 
To convert mg/dl of triglycerides to mmol/l, divide by 88.57. 
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 Objective: Insulin resistance is considered a potential etiology underlying 
endothelial dysfunction and dyslipidemia associated with metabolic syndrome. Metabolic 
syndrome increases the risk for CAD and diabetes. Early identification of metabolic 
syndrome may prevent progression and complications associated with these diseases. 
 Methods: An on-line review of published literature through various search 
engines including Medline, MD Consult, CINAHL, Google, and PubMed of subjects 
applying but not limited to search terms: metabolic syndrome, insulin resistance, 
syndrome x, dyslipidemia, and diabetes was conducted to compare and contrast 
simplicity and accuracy of various IR detection models.  
 Results: None of the currently reviewed models are practical for clinical 
application in identifying insulin resistance in large, general populations.   
 Conclusion: The use of newly established guidelines set by the National 
Cholesterol Education Panel for metabolic syndrome is currently the most effective 
clinical screening method available for identifying insulin resistance.  
 
 